You’re invited to participate in a free focus group with NHF that will help inspire future education resources related to joint health and pain management. Register now to join an insightful, online discussion on Thursday, July 21…
FOR IMMEDIATE RELEASEMEDIA CONTACT:Ilana Ostrin212 328 3769Patients, families and caregivers reunite at the 2022 Bleeding Disorders ConferenceJuly 12, 2022 - HOUSTON, TEXAS - After two years of coming together…
NEW YORK – Dr. Marion Koerper, a legendary pediatric hematologist, is solidifying her longtime relationship with the National Hemophilia Foundation thanks to a new research fund established in her honor.
Elevating a Future of…
NHF’s Medical and Scientific Advisory Council (MASAC) has approved a new recommendation on genotyping for people with hemophilia, which were endorsed by the NHF Board of Directors on July 6th.
The document provides a brief historic background of…
Matt Delaney joined NBDF in 2022 as Government Relations Manager, where he assists NBDF chapters in advocacy and policy, and contributes to the foundation’s federal and international work on blood and product safety and supply. As a person who lives…
Meet NHF's Chapter Development Specialist, Nick Kallinicou! Nick took his passion for meaningful and impactful work and joined NHF. He continues to be a vital part of the NHF community and assisting families and patients. Learn more about…
Amy L. Dunn. MD is a Professor of Pediatrics at Nationwide Children's Hospital, the Ohio State University College of Medicine where she is the Director of Pediatric Hematology and directs the Hemostasis Treatment Center. Dr Dunn received her medical…
FOR IMMEDIATE RELEASE
Abortion and contraception can both be critical components of an individual’s health care journey. However, it is important to not conflate abortion and birth control as one in the same – both are medical in…
Sanofi and Swedish Orphan Biovitrum AB (Sobi®) recently shared positive results from the XTEND-1 pivotal phase 3 study of efanesoctocog alfa (BIVV001).
BIVV001 is an investigational recombinant factor VIII therapy (rFVIII) developed for the…